CD20

CD20 in the glossary for Waldenström's macroglobulinemia

An antigen expressed on the surface of B-cells

CD20 (also known as B-lymphocyte antigen CD20) is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increases in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. The protein functions to enable optimal B-cell immune response, specifically against T-independent antigens. CD20 is the target of several monoclonal antibodies (such as rituximab, obinutuzumab, and ibritumomab) which are active agents in the treatment of all B-cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.¹

Glossary overview

References

1.Boross P and Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012: 2(6);676-690

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.